Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Video: Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy

Thursday, December 11, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a novel method for analyzing transcription factor protected cfDNA in plasma using ChIP-seq. This approach highlights altered CTCF binding in cancer, presenting it as a new biomarker for liquid biopsy. The findings suggest significant potential for enhancing cancer diagnostics and prognostic assessments.
Price reaction · baseline $5.6 (2025-12-10 close) · hit pre-market · clean, no other VNRX news in the window
day 0 close
+2.6%
day 1
-3.9%
day 3 · peak
-13.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Novel biomarker for liquid biopsy identified.
  • Direct analysis method may enhance cancer diagnostics.
  • Potential for improved prognostic value in cancer testing.

Full Press Release Details

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the article?

The article focuses on a novel method for analyzing cfDNA in plasma to identify cancer biomarkers.

What does ChIP-seq analyze?

ChIP-seq analyzes transcription factor protected cfDNA to measure altered binding in cancer.

How can this method improve cancer diagnostics?

This method may enhance cancer diagnostics by providing a new biomarker for liquid biopsy.

What is CTCF binding's significance?

Altered CTCF binding is highlighted as a novel biomarker for cancer detection.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare cfDNA CTCF binding cancer diagnostics liquid biopsy
Last updated: Dec 11, 2025

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk